Lotte Biologics Participates in 'Bio Japan 2023'... "Discovering Potential Clients"

Strengthening Partnerships with Asian Companies

Lotte Biologics announced on the 11th that it will participate in the 'BIO Japan 2023' conference held at the Pacifico Yokohama National Convention Hall in Yokohama, Japan, until the 13th.

Lotte Biologics BIO Japan 2023 Booth.
Photo by Lotte Biologics

BIO Japan is Asia's largest bio partnering event, which has been held since 1986. Through major programs such as exhibitions, seminars, and partnering, it supports open innovation activities of global pharmaceutical and bio companies every year.

This is the first time Lotte Biologics is attending a bio conference in the Japanese region. Taking this opportunity, the company plans to strengthen its presence in Japan and enhance business partnering with companies in the Asian region.

At this event, Lotte Biologics will operate a solo booth and introduce its competitiveness, including mid- to long-term business strategies through its Syracuse site in the U.S. and the Songdo bio plant in Korea, the establishment of bio venture initiatives, and capabilities in antibody-drug conjugate (ADC) technology platforms.

Kim Kyung-eun, Head of Business Development at Lotte Biologics, stated, "Due to the recent pandemic, the pharmaceutical supply chain in the Asian region has faced a crisis, increasing the importance of pharmaceutical contract manufacturing and development. Through BIO Japan 2023, we plan to focus on discovering potential clients within the Asian region, in addition to the U.S. and European markets where we have already built networks."

Meanwhile, Lotte Biologics will also attend 'CPHI Barcelona 2023,' held from the 24th to the 26th of this month in Barcelona, Spain. Through this, the company plans to continuously create touchpoints with global companies and strengthen its order-winning competitiveness.

This content was produced with the assistance of AI translation services.